Table 1.
Clinical and Pathological Features of the Patients Treated with Lenvatinib
| Patient No., Sex | Tumor histotype, variant | Metastasis | ECOG status | Age at lenvatinib, start (years) | Lenvatinib starting dose (mg) | Follow-up (months) | PAI (yes/no) | PAI diagnosis after lenvatinib started (months) | AEs (Grade)a |
|---|---|---|---|---|---|---|---|---|---|
| 1, F | PTC, classic | Lung, neck | 0 | 63 | 14 | 6 | No | / | Hypertension (2), proteinuria (1), fatigue (2), palmar plantar erythrodysesthesia syndrome (1), arthralgia/myalgia (1) |
| 2, M | Hurthle cell | Lymph nodes, lung | 0 | 44 | 24 | 28 | No | / | Hypertension (1), proteinuria (1) |
| 3, F | PTC, solid | Lymph nodes, lung | 0 | 40 | 24 | 9 | No | / | Hypertension (1), proteinuria (1), diarrhea (2) |
| 4, M | FTC | Lung, neck, bone | 0 | 77 | 20 | 6 | Yes | 3 | Hypertension (2), proteinuria (1), fatigue (2), diarrhea (2), stomatitis (1), palmar plantar erythrodysesthesia syndrome (1), dysphonia (1) |
| 5, M | FTC | Lymph nodes, lung | 1 | 79 | 24 | 29 | No | / | Hypertension (2), proteinuria (1), fatigue (3), diarrhea (2), weight loss (3) stomatitis (1), nausea/vomiting (1) |
| 6, F | PTC, classic | Lung, bone | 1 | 75 | 14 | 24 | Yes | 3 | Hypertension (2), proteinuria (2), fatigue (3), weight loss (2), stomatitis (1), nausea/vomiting (1), dysphonia (1) |
| 7, F | PTC, classic | Lymph nodes, lung | 1 | 82 | 10 | 6 | No | / | Hypertension (1), fatigue (1), diarrhea (1), weight loss (1), stomatitis (1) |
| 8, F | PTC, tall cell | Lymph nodes, lung | 0 | 67 | 24 | 15 | Yes | 3 | Hypertension (2), fatigue (2), stomatitis (2), palmar plantar erythrodysesthesia syndrome (3) |
| 9, M | PTC, tall cell | Bone, neck | 0 | 73 | 24 | 15 | Yes | 9 | Hypertension (2), fatigue (3), diarrhea (2), weight loss (2), stomatitis (1), palmar plantar erythrodysesthesia syndrome (1) |
| 10, F | PTC, classic | Lung, bone | 0 | 61 | 24 | 29 | Yes | 18 | Hypertension (2), fatigue (3), diarrhea (1), weight loss (3), stomatitis (1), palmar plantar erythrodysesthesia syndrome (2), nausea/vomiting (1), dysphonia (1), alopecia (1) |
| 11, F | PTC, solid | Lymph nodes, lung, bone | 0 | 68 | 24 | 29 | Yes | 6 | Hypertension (2), proteinuria (2), fatigue (2), diarrhea (2), weight loss (2) |
| 12, F | PTC, follicular | Lymph nodes, lung | 1 | 66 | 24 | 27 | Yes | 12 | Hypertension (2), proteinuria (1), fatigue (2), weight loss (3) |
| 13, M | PTC, tall cell | Lymph nodes, lung, bone, brain | 0 | 56 | 20 | 6 | No | / | Hypertension (2), fatigue (2), weight loss (2), nausea/vomiting (1) |
Some AEs of lenvatinib treatment may be symptoms related to PAI: fatigue, weight loss, diarrhea, nausea, and vomiting. In our study, only fatigue was associated with PAI (see the Results and Discussion sections); none of the other symptoms was significantly associated with PAI.
a
AEs were assessed using the National Cancer Institute CTCAE version 4.03 (9).
AEs, adverse events; CTCAE, Common Terminology Criteria for Adverse Events; ECOG, Eastern Cooperative Oncology Group; F, female; FTC, follicular thyroid cancer; M, male; PAI, primary adrenal insufficiency; PTC, papillary thyroid cancer.